Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


6 Clin Infect Dis
3 J Infect
12 J Infect Dis
1 J Pediatr
3 J Virol
1 Lancet
2 N Engl J Med
1 Nat Immunol
1 Nat Med
5 PLoS One
11 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


    Covid-19: Fourth dose of mRNA vaccines is safe and boosts immunity, study finds.
    BMJ. 2022;377:o1170.

  2. KWAN R
    How Hong Kong's vaccination missteps led to the world's highest covid-19 death rate.
    BMJ. 2022;377:o1127.

    Sixty seconds on . . . nasal vaccines.
    BMJ. 2022;377:o1148.

    Clin Infect Dis

  4. POH XY, Tan CW, Lee IR, Chavatte JM, et al
    Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A Randomized Clinical Trial.
    Clin Infect Dis. 2022 May 11. pii: 6583615. doi: 10.1093.
    PubMed         Abstract available

  5. CONTI MG, Terreri S, Terrin G, Natale F, et al
    SARS-CoV-2 infection versus vaccination in pregnancy: Implications for maternal and infant immunity.
    Clin Infect Dis. 2022 May 10. pii: 6583148. doi: 10.1093.
    PubMed         Abstract available

  6. SPARKE M, Levy O
    Competing responses to global inequalities in access to COVID vaccines: Vaccine Diplomacy and Vaccine Charity Versus Vaccine Liberty.
    Clin Infect Dis. 2022 May 10. pii: 6583150. doi: 10.1093.
    PubMed         Abstract available

  7. ZURCHER K, Abela IA, Stange M, Dupont C, et al
    Alpha variant coronavirus outbreak in a nursing home despite high vaccination coverage: molecular, epidemiological and immunological studies.
    Clin Infect Dis. 2022 May 6. pii: 6582009. doi: 10.1093/cid/ciab1005.
    PubMed         Abstract available

  8. BHIMRAJ A, Morgan RL, Shumaker AH, Lavergne V, et al
    Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-Edged Swords.
    Clin Infect Dis. 2021 Oct 20. pii: 6398590. doi: 10.1093.
    PubMed         Abstract available

  9. BEN-SHIMOL S, Regev-Yochay G, Givon-Lavi N, van der Beek BA, et al
    Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance.
    Clin Infect Dis. 2022;74:1639-1649.
    PubMed         Abstract available

    J Infect

  10. MARSAY L, Dold C, Paterson GK, Yamaguchi Y, et al
    Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.
    J Infect. 2022;84:658-667.
    PubMed         Abstract available

  11. AU WY, Ye C, Briner SL, Suarez GD, et al
    Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00123.

  12. DIMEGLIO C, Migueres M, Chapuy-Regaud S, Da-Silva I, et al
    Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response.
    J Infect. 2022 May 7. pii: S0163-4453(22)00258.

    J Infect Dis

  13. SIRIVICHAYAKUL C, Barranco-Santana EA, Rivera IE, Kilbury J, et al
    Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
    J Infect Dis. 2022;225:1513-1520.
    PubMed         Abstract available

  14. MITSI E, McLenaghan D, Wolf AS, Jones S, et al
    Thirteen-Valent Pneumococcal Conjugate Vaccine-Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung.
    J Infect Dis. 2022;225:1626-1631.
    PubMed         Abstract available

  15. GIURGEA LT, Cervantes-Medina A, Walters KA, Scherler K, et al
    Sex Differences in Influenza: The Challenge Study Experience.
    J Infect Dis. 2021 Aug 23. pii: 6356350. doi: 10.1093.
    PubMed         Abstract available

  16. GORSE GJ, Rattigan SM, Kirpich A, Simberkoff MS, et al
    Influence of Pre-Season Antibodies against Influenza Virus on Risk of Influenza Infection among Health Care Personnel.
    J Infect Dis. 2021 Sep 17. pii: 6371937. doi: 10.1093.
    PubMed         Abstract available

  17. MOHAN VR, Srinivasan M, Sinha B, Shrivastava A, et al
    Geographically Weighted Regression Modeling of Spatial Clustering and Determinants of Focal Typhoid Fever Incidence.
    J Infect Dis. 2021;224.
    PubMed         Abstract available

  18. SINHA B, Rongsen-Chandola T, Goyal N, Arya A, et al
    Incidence of Enteric Fever in a Pediatric Cohort in North India: Comparison with Estimates from 20 Years Earlier.
    J Infect Dis. 2021;224.
    PubMed         Abstract available

  19. CAO Y, Karthikeyan AS, Ramanujam K, Raju R, et al
    Geographic Pattern of Typhoid Fever in India: A Model-Based Estimate of Cohort and Surveillance Data.
    J Infect Dis. 2021;224.
    PubMed         Abstract available

  20. LIU B, Stepien S, Pye V, Law C, et al
    High attack rate of SARS-CoV-2 B.1.1.529 among two-dose vaccinated populations in two indoor entertainment setting outbreaks.
    J Infect Dis. 2022 May 7. pii: 6582820. doi: 10.1093.
    PubMed         Abstract available

  21. MUHR LSA, Eklund C, Lagheden C, Eriksson T, et al
    Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses.
    J Infect Dis. 2022 May 10. pii: 6582940. doi: 10.1093.
    PubMed         Abstract available

  22. EL SAHLY HM, Baden LR, Essink B, Montefiori D, et al
    Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial.
    J Infect Dis. 2022 May 10. pii: 6583011. doi: 10.1093.
    PubMed         Abstract available

  23. MWIMANZI F, Lapointe HR, Cheung PK, Sang Y, et al
    Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose.
    J Infect Dis. 2022 May 11. pii: 6583561. doi: 10.1093.
    PubMed         Abstract available

  24. BABER J, Arya M, Moodley Y, Jaques A, et al
    A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    J Infect Dis. 2022 May 11. pii: 6583554. doi: 10.1093.
    PubMed         Abstract available

    J Pediatr

  25. BANZHOFF A, Martinon-Torres F
    Meningococcal B vaccine effectiveness.
    J Pediatr. 2022;244:250-254.

    J Virol

  26. NGUYEN HT, Qualizza A, Anang S, Zhao M, et al
    Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.
    J Virol. 2022 Mar 28:e0166821. doi: 10.1128/jvi.01668.
    PubMed         Abstract available

  27. MANTLO EK, Maruyama J, Manning JT, Wanninger TG, et al
    Machupo Virus with Mutations in the Transmembrane Domain and Glycosylation Sites of the Glycoprotein Is Attenuated and Immunogenic in Animal Models of Bolivian Hemorrhagic Fever.
    J Virol. 2022;96:e0020922.
    PubMed         Abstract available

  28. LINVILLE AC, Rico AB, Teague H, Binsted LE, et al
    Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.
    J Virol. 2022 May 11:e0039822. doi: 10.1128/jvi.00398.
    PubMed         Abstract available


    Four Vaccine Doses Prevented Severe Omicron COVID-19 Better Than 3.
    JAMA. 2022;327:1748.

    Two mRNA COVID-19 Vaccines Stimulate Different Immune Responses.
    JAMA. 2022;327:1748.

  31. KUEHN BM
    Age Range Is Expanded for Universal Hepatitis B Vaccination.
    JAMA. 2022;327:1749.

  32. KUEHN BM
    mRNA Booster Improves a COVID-19 Vaccine's Effectiveness.
    JAMA. 2022;327:1749.


  33. DZAU VJ, Balatbat CA, Offodile AC 2nd
    Closing the global vaccine equity gap: equitably distributed manufacturing.
    Lancet. 2022 May 6. pii: S0140-6736(22)00793.

    N Engl J Med

  34. CREECH CB, Anderson E, Berthaud V, Yildirim I, et al
    Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
    N Engl J Med. 2022 May 11. doi: 10.1056/NEJMoa2203315.
    PubMed         Abstract available

  35. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
    Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
    N Engl J Med. 2022 Apr 5. doi: 10.1056/NEJMoa2201570.
    PubMed         Abstract available

    Nat Immunol

  36. LUSTIG Y, Gonen T, Meltzer L, Gilboa M, et al
    Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose.
    Nat Immunol. 2022 May 9. pii: 10.1038/s41590-022-01212.
    PubMed         Abstract available

    Nat Med

  37. MOLINO D, Durier C, Radenne A, Desaint C, et al
    A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.
    Nat Med. 2022 May 5. pii: 10.1038/s41591-022-01785.

    PLoS One

  38. OKUNLOLA OA, Oyeyemi OT
    Malaria transmission in Africa: Its relationship with yellow fever and measles.
    PLoS One. 2022;17:e0268080.
    PubMed         Abstract available

  39. HIJANO DR, Hoffman JM, Tang L, Schultz-Cherry SL, et al
    An adaptive, asymptomatic SARS-CoV-2 workforce screening program providing real-time, actionable monitoring of the COVID-19 pandemic.
    PLoS One. 2022;17:e0268237.
    PubMed         Abstract available

  40. FARIA DE CARVALHO R, de Siqueira Penna Quintaes L, de Cassia de Souza Su T, Mitiko Kobayashi L, et al
    Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells.
    PLoS One. 2022;17:e0267653.
    PubMed         Abstract available

  41. FREUND O, Tau L, Weiss TE, Zornitzki L, et al
    Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era.
    PLoS One. 2022;17:e0268050.
    PubMed         Abstract available

  42. OLU-ABIODUN O, Abiodun O, Okafor N
    COVID-19 vaccination in Nigeria: A rapid review of vaccine acceptance rate and the associated factors.
    PLoS One. 2022;17:e0267691.
    PubMed         Abstract available


  43. COLE JW, Chen AMH, McGuire K, Berman S, et al
    Erratum to "Motivational interviewing and vaccine acceptance in children: The MOTIVE study" [Vaccine 40(12) (2022) 1846-1854].
    Vaccine. 2022 May 5. pii: S0264-410X(22)00538.

  44. VELICER C, Luxembourg A, Chen YT, Kohn M, et al
    Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00542.

  45. NASREEN S, Calzavara A, Buchan SA, Thampi N, et al
    Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
    Vaccine. 2022 Apr 27. pii: S0264-410X(22)00520.
    PubMed         Abstract available

  46. PERSSON U, Olofsson S, Althin R, Palmborg A, et al
    Acceptance and application of a broad population health perspective when evaluating vaccine.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00425.
    PubMed         Abstract available

  47. LIU W, Lien YH, Lee PI, Chan TC, et al
    Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health.
    Vaccine. 2022 May 4. pii: S0264-410X(22)00358.
    PubMed         Abstract available

  48. YU Y, Ma YL, Luo S, Wang S, et al
    Prevalence and factors of influenza vaccination during the COVID-19 pandemic among university students in China.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00532.
    PubMed         Abstract available

  49. HUSSAIN B, Latif A, Timmons S, Nkhoma K, et al
    Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies.
    Vaccine. 2022 Apr 28. pii: S0264-410X(22)00446.
    PubMed         Abstract available

  50. LUMBRERAS ARETA M, Valiton A, Diana A, Morales M, et al
    Flu and pertussis vaccination during pregnancy in Geneva during the COVID-19 pandemic: A multicentric, prospective, survey-based study.
    Vaccine. 2022 May 6. pii: S0264-410X(22)00533.
    PubMed         Abstract available

  51. CROTHERS JW, Ross Colgate E, Cowan KJ, Dickson DM, et al
    Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus sero
    Vaccine. 2022 May 6. pii: S0264-410X(22)00571.

  52. BOTHUN LS, Feeder SE, Poland GA
    Readability of COVID-19 vaccine information for the general public.
    Vaccine. 2022 May 3. pii: S0264-410X(22)00546.
    PubMed         Abstract available

  53. BIFULCO M, Di Zazzo E, Pisanti S, Martini M, et al
    The nineteenth-century experience of the kingdom of the two Sicilies on mandatory vaccination: An Italian phenomenon?
    Vaccine. 2022 May 6. pii: S0264-410X(22)00492.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.